IMO paxalisib is fortunate to partisipate and be tested in the GBM AGILE FDA approved registration phase111 trial. Dr James Garner commented in a recent presentation about how GBM AGILE is going gangbusters at the moment with 800 screened patients, well ahead of schedule. The number of recruited patients in the study arms are proceeding exceptionally well. Paxalisib delays are not evident at the moment, so don't worry be happy.
Regards.
KZA Price at posting:
$1.58 Sentiment: Buy Disclosure: Held